Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
Affiliation
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2011
Metadata
Show full item recordAbstract
Despite discrepant results on clinical utility, several trials are already prospectively randomizing non-small cell lung cancer (NSCLC) patients by ERCC1 status. We aimed to characterize the prognostic and predictive effect of ERCC1 by systematic review and meta-analysis.Citation
Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. 2011, 6 (10):e25164 PLoS ONEJournal
PloS OneDOI
10.1371/journal.pone.0025164PubMed ID
22022380Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0025164